Steven Wassilak researcher
Wassilak, Steven G. F.
VIAF ID: 6582161 (Personal)
Permalink: http://viaf.org/viaf/6582161
Preferred Forms
- 100 0 _ ‡a Steven Wassilak ‡c researcher
- 100 1 _ ‡a Wassilak, Steven G. F.
- 100 1 0 ‡a Wassilak, Steven G. F.
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Estimated effects of a delay in the recommended vaccination schedule for diphtheria and tetanus toxoids and pertussis vaccine | |
Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled | |
An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease | |
The Globally Synchronized Switch-Another Milestone Toward Achieving Polio Eradication | |
Health impact of measles vaccination in the United States | |
Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis | |
Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial. | |
Incidence of invasive Haemophilus influenzae type b disease in Italian children | |
Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination | |
Is there a need of "catch-up' polio vaccination in preadolescence? | |
Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis | |
Laboratory diagnosis of pertussis: the state of the art | |
Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Bangladesh | |
Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation | |
Measles outbreaks in religious groups exempt from immunization laws | |
Measles seroconfirmation using dried capillary blood specimens in filter paper | |
Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. | |
Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria | |
Modeling population immunity to support efforts to end the transmission of live polioviruses | |
Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination | |
Monitoring of adverse events following immunization in the Expanded Programme of Immunization, 1991: | |
Neonatal tetanus: potential for elimination in the world | |
New analytic approaches for analyzing and presenting polio surveillance data to supplement standard performance indicators | |
Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015. | |
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). | |
Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population | |
Outbreaks of paralytic poliomyelitis during 1996-2012: the changing epidemiology of a disease in the final stages of eradication | |
Outbreaks of pertussis in the United States: the Wisconsin experience | |
Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication | |
Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group | |
Pertussis epidemic in Oklahoma. Difficulties in preventing transmission | |
Pertussis immunization: results of new trials | |
Polio-free certification and lessons learned--South-East Asia region, March 2014. | |
Polio outbreak in Albania, 1996 | |
Polio priority countries and the 2018 Hajj: Leveraging an opportunity | |
Poliomyelitis outbreaks in Angola genetically linked to India: risk factors and implications for prevention of outbreaks due to wild poliovirus importations | |
Poliomyelitis vaccination strategies for Europe | |
Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010. | |
Possible eradication of wild poliovirus type 3--worldwide, 2012. | |
The potential impact of expanding target age groups for polio immunization campaigns | |
Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines | |
Preeradication vaccine policy options for poliovirus infection and disease control. | |
Preventing congenital rubella infection in the European Region of WHO: 2010 target | |
Progress in Europe towards the goal of poliomyelitis eradication | |
Randomised study of the possible adjuvant effect of BCG vaccine on the immunogenicity of diphtheria-tetanus-acellular pertussis vaccine in Senegalese infants. | |
Reduced dose of DTP vaccine | |
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs | |
Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team | |
Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study | |
The role of older children and adults in wild poliovirus transmission | |
Seroepidemiology of diphtheria and tetanus among children and young adults in Tajikistan: nationwide population-based survey, 2010. | |
Surveillance during an era of rapidly changing poliovirus epidemiology in India: the role of one vs. two stool specimens in poliovirus detection, 2000-2010. | |
Tracking progress toward polio eradication - worldwide, 2013-2014. | |
Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response | |
Update on Vaccine-Derived Poliovirus Outbreaks - Democratic Republic of the Congo and Horn of Africa, 2017-2018 | |
Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013. | |
Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain | |
Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart | |
Using Acute Flaccid Paralysis Surveillance as a Platform for Vaccine-Preventable Disease Surveillance | |
Utility of large-linked databases in vaccine safety, particularly in distinguishing independent and synergistic effects. The Vaccine Safety Datalink Investigators | |
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984 | |
Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team | |
What we are watching--five top global infectious disease threats, 2012: a perspective from CDC's Global Disease Detection Operations Center | |
What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003-2009 and essential accelerated actions | |
World Health Organization regional assessments of the risks of poliovirus outbreaks |